A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.


Updates from The Motley Fool

Latest updates on Repligen from Fool.com.
3 Growth Stocks to Buy for 2018

Atlassian, SolarEdge, and Repligen have promising growth trajectories in the year -- and years --...



Stock Performance

View Interactive RGEN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Repligen.
Current Price: $65.45
Prev Close: $64.05
Open: $63.89
Bid: $62.10
Ask: $66.90
Day's Range: $63.74 - $66.59
52wk Range: $29.56 - $70.50
Volume: 557,357
Avg Vol 564,851
Market Cap: $3B
P/E (ttm): 120.85
EPS (ttm): $0.53
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Repligen.
CAPS Rating 4 out of 5
 
446 Outperform
11 Underperform
CAPS All Stars
 
88 Outperform
4 Underperform

How do you think Repligen will perform against the market?



You pick for Repligen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Tony J. Hunt, CEO

100% Approve

Based on 7 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Repligen.

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers